Is TLX or TNYA more undervalued in 2026?

CirclFi compares Telix Pharmaceuticals Limited (TLX) and Tenaya Therapeutics, Inc. (TNYA) using 13 institutional-grade valuation models. TLX has a Quality of Company score of 3.3/10 while TNYA scores 4.1/10.

Which is a better buy — TLX or TNYA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TLX and TNYA valuations compare?

TLX at $9.53 and TNYA at $0.80 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TLX vs TNYA Valuation Comparison 2026 — Intrinsic Value Analysis

TLX

Biotechnology

Telix Pharmaceuticals Limited

Quality

3.3

out of 10

Value Trap

—

Price

$9.53

Last close

Models

12/13

Active

TNYA

Biotechnology

Tenaya Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

LOW

Price

$0.80

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	TLX Fair Value	TLX Upside	TNYA Fair Value	TNYA Upside
Bayesian DCF	Intrinsic	$2.81	-70.5%	$0.40	-50.0%
Earnings Power Value	Intrinsic	$1.36	-87.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.61	-93.7%	$0.79	-1.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TLX vs TNYA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TLX vs TNYA — Which Stock Is More Undervalued?

TNYA scores higher with a 4.1/10 quality rating vs TLX's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Telix Pharmaceuticals Limited (TLX) and Tenaya Therapeutics, Inc. (TNYA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TLX currently trades at $9.53 with a QOC of 3.3/10, while TNYA trades at $0.80 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).